Table 5.

Effect of acute i.d. injection of vehicle, alosetron and tegaserod on MAP, HR, CBF and CVC of fasted rats

Treatment and recording period	MAP (mmHg)	HR (beats·min−1)	CBF (PU)	CVC [PU·(mmHg)−1]
Vehicle (10% NMP) 15–0 min pre	89.3 ± 5.39	396 ± 22.1	392 ± 48.6	4.52 ± 0.73
Vehicle (10% NMP) 0–15 min post	86.6 ± 5.54	393 ± 23.0	399 ± 49.8	4.75 ± 0.80
Vehicle (10% NMP) 15–30 min post	86.1 ± 5.64	392 ± 22.8	405 ± 52.0	4.84 ± 0.83
Vehicle (10% NMP) 45–60 min post	87.1 ± 4.84	403 ± 22.7	409 ± 51.9	4.87 ± 0.88
Vehicle (10% NMP) 75–90 min post	87.0 ± 5.21	422 ± 24.5*	405 ± 56.3	4.86 ± 0.95
Alosetron (0.3 mg·kg−1) 15–0 min pre	92.7 ± 3.58	358 ± 16.8	399 ± 51.5	4.34 ± 0.59
Alosetron (0.3 mg·kg−1) 0–15 min post	90.3 ± 4.95	352 ± 14.2	396 ± 53.3	4.46 ± 0.63
Alosetron (0.3 mg·kg−1) 15–30 min post	91.7 ± 5.63	348 ± 14.2	395 ± 57.2	4.36 ± 0.61
Alosetron (0.3 mg·kg−1) 45–60 min post	91.7 ± 5.81	355 ± 14.4	404 ± 53.6	4.42 ± 0.55
Alosetron (0.3 mg·kg−1) 75–90 min post	91.3 ± 4.96	357 ± 13.1	410 ± 51.0	4.50 ± 0.55
Tegaserod (30 mg·kg−1) 15–0 min pre	81.9 ± 3.37	372 ± 8.93	392 ± 60.1	4.83 ± 0.74
Tegaserod (30 mg·kg−1) 0–15 min post	79.1 ± 3.86	372 ± 11.7	391 ± 61.5	5.06 ± 0.86
Tegaserod (30 mg·kg−1) 15–30 min post	79.3 ± 3.60	371 ± 11.8	370 ± 46.6	4.77 ± 0.66
Tegaserod (30 mg·kg−1) 45–60 min post	84.9 ± 3.70	383 ± 14.0	377 ± 60.3	4.56 ± 0.81
Tegaserod (30 mg·kg−1) 75–90 min post	85.1 ± 2.72	386 ± 13.5**	379 ± 56.3	4.49 ± 0.70

The experimental parameters were recorded and averaged during the pre-injection and post-injection periods as indicated. Means ± SEM, n= 7–8.

^*P < 0.05,

^**P < 0.01 versus pre-injection (one-way anova for repeated measures followed by the Bonferroni test).

CBF, colonic blood flow; CVC, colonic vascular conductance; HR, heart rate; MAP, mean arterial blood pressure; NMP, 1-methyl-2-pyrrolidone; PU, perfusion unit.